IFNA1 and acquired polycythemia vera: Clinical trial data from a phase II study of combination therapy with Peg-IFN and ruxolitinib in MPNs patients who are resistant and/or intolerant to IFN monotherapy have confirmed that CHR in patients with PV was 44% after 12 months of treatment (29).